Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma.

ABSTRACT:

Background

Molecular profiling allows tumor classification as well as assessment of diagnostic, prognostic, and treatment-related molecular changes. Translation into clinical practice and relevance for patients has not been demonstrated yet.

Methods

We analyzed clinical and molecular data of isocitrate dehydrogenase wild-type glioblastoma patients with sufficient clinical follow-up from the Heidelberg Neuro-Oncology Center and with molecular analysis of tumor tissue that consisted of DNA methylation array data, genome-scale copy number variations, gene panel sequencing, and partly mTOR immunohistochemistry between October 2014 and April 2018.

Results

Of 536 patients screened, molecular assessment was performed in 253 patients (47%) in a prospective routine clin

SUBMITTER: Kessler T 

PROVIDER: S-EPMC7212885 | biostudies-literature | 2020 Jan-Dec

REPOSITORIES: biostudies-literature